Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, MD, PhD, on Prostate Cancer: Results of the SPCG-13 Trial
2018 ASCO Annual MeetingPirkko-Liisa Irmeli Kellokumpu-Lehtinen, MD, PhD, of Tampere University Hospital, discusses phase III findings on adjuvant docetaxel and surveillance after radical radiotherapy for intermediate- and high-risk prostate cancer (Abstract 5000).
Related Videos
Gianni Bisogno, MD, on Rhabdomyosarcoma: Results From the European Paediatric Soft Tissue Sarcoma Study Group
Gianni Bisogno, MD, of the University Hospital of Padova, discusses study findings on maintenance low-dose chemotherapy in patients with high-risk rhabdomyosarcoma (Abstract LBA2)....
Susan Halabi, PhD, on Prostate Cancer: Overall Survival for Black vs White Men
Susan Halabi, PhD, of Duke University Medical Center, discusses an analysis that showed an increase in overall survival in African American men vs Caucasian men, all of whom had me...
Ryan D. Nipp, MD, on Electronic Symptom Monitoring: Trial Results
Ryan D. Nipp, MD, of Massachusetts General Hospital, discusses study findings on electronic symptom monitoring vs usual care to assess whether the intervention, tested in hospitali...
Joseph A. Sparano, MD, on Breast Cancer: Results of the TAILORx Trial
Joseph A. Sparano, MD, of Montefiore Medical Center, discusses phase III study results on chemoendocrine treatment vs endocrine treatment alone in hormone receptor–positive, HER2-n...
Lee S. Schwartzberg, MD, on Using Immunotherapy in the Community Setting: 2018 Update on an ACCC Program
Lee S. Schwartzberg, MD, of West Cancer Center, reports on the progress of the ACCC Immuno-Oncology Institute to speed adoption of immunotherapeutics in community practices.
